Several clinical trials have shown that patients receiving combination therapy of a GLP-1R agonist and sulfonylurea (SU), a KATP inhibitor, have a higher incidence of hypoglycemia than those treated with a GLP-1R agonist only [96,97]. Here, GLP1R is linked to Hypoglycemia.